Umów wizytę

Tomasz Poboży

Kategoria: Patient News (EN)

Short, evidence-checked patient-facing updates on new medical and orthopaedic research, with clear context about study stage and limitations.

  • Teclistamab Before Symptomatic Myeloma: Promising Phase 2 Results

    General Medical Discoveries · Human study — phase 2

    Researchers tested teclistamab in people with high-risk smoldering multiple myeloma, a precursor condition that has not yet caused the typical organ damage of active multiple myeloma but carries a substantial risk of progression. In this randomized phase 2 study, teclistamab produced much deeper responses than lenalidomide plus dexamethasone; at two years, progression-free survival was estimated at 92% with teclistamab and 49% with the comparison treatment. The result is important because it explores whether disease can be intercepted before symptomatic myeloma develops. An orthopaedic surgeon interpreting this haematology study should note that it was still small—59 people were treated—and that longer follow-up is needed to establish durability, overall-survival effects and longer-term safety. Teclistamab remains experimental in this setting, and these findings do not mean that every person with smoldering myeloma should receive treatment.

    Source: Nadeem O, Cordas dos Santos DM, Magidson S, et al. Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial. Nature Medicine. Published online 11 September 2026. DOI: 10.1038/s41591-026-04642-w. ClinicalTrials.gov: NCT05469893. Verified 15 September 2026 against the open-access full article and PubMed record.

    Polish version · More General Medical Discoveries

    Content prepared by: Tomasz Poboży - orthopaedic surgeon.

  • One CRISPR Infusion, Effects Still Seen at One Year: Early Lipid-Lowering Data

    General Medical Discoveries · Human study — phase 1a

    Researchers followed participants in an early phase 1a study who received a one-time infusion of CTX310, an experimental CRISPR-Cas9 therapy designed to edit the ANGPTL3 gene in the liver. At one year, reductions in ANGPTL3 protein and atherogenic lipids were still present, and the published report described no treatment-related dose-limiting toxic effects. This is an interesting signal for people with difficult-to-treat lipid disorders, but the research remains at a very early stage. An orthopaedic surgeon following developments in gene editing should distinguish a biomarker change from a patient benefit: it is not yet known whether permanent gene editing will reduce the risk of heart attack or stroke, or what its safety profile will look like over many years. CTX310 remains an experimental treatment.

    Source: Laffin LJ, Nicholls SJ, Scott RS, et al. Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310. New England Journal of Medicine. Published online 28 August 2026. DOI: 10.1056/NEJMc2609825. Verified 15 September 2026 against the NEJM article page and PubMed record. The public abstract and article page were reviewed; the full letter was not analysed.

    Polish version · More General Medical Discoveries

    Content prepared by: Tomasz Poboży - orthopaedic surgeon.

  • Hip Arthroscopy After 40 — What Does the New Review Show?

    A new systematic review suggests that carefully selected patients aged 40 or older can have durable improvement after hip arthroscopy for femoroacetabular impingement syndrome (FAIS). This does not mean that age no longer matters, or that surgery is better than non-operative treatment for every patient.

    What was studied?

    The review, published online on 14 September 2026, included nine studies with 451 patients and 467 hips. Follow-up ranged from 60 to 167 months — five years to almost fourteen years. The studies evaluated people aged at least 40 who underwent hip arthroscopy for FAIS.

    What did the review find?

    Across the included studies, pain and functional outcome scores generally improved and the gains were often maintained at longer follow-up. When comparisons with younger groups were available, age-related differences were not consistent. Some patients nevertheless later underwent total hip arthroplasty; reported conversion rates ranged from 2.9% to 13.2%.

    What should a patient discuss with an orthopaedic surgeon?

    Being over 40 should not, by itself, determine whether hip arthroscopy is appropriate. Symptoms, clinical examination, the condition of the cartilage and labrum, radiographic findings and whether the presentation is actually consistent with FAIS all matter.

    The review did not provide a randomised comparison of arthroscopy with a well-delivered rehabilitation programme. It therefore cannot establish that surgery is the best first option. Rather, it shows that improvement after arthroscopy can be durable in selected patients over 40, while the risk of later joint replacement is not zero.

    Important limitations

    The review combined studies of differing quality and was classified as Level IV evidence. Patient groups, procedures and outcome reporting varied, so the numerical ranges are not a prediction for an individual patient. This summary was prepared from the public abstract and bibliographic record; the full text was not used. The PubMed record showed no correction or retraction when checked on 15 September 2026.

    Source

    Lehman AC, Lee S, Berzolla E, Lezak BA, Youm T. Hip Arthroscopy for Femoroacetabular Impingement Syndrome in Patients Aged ≥40 Years Produces Durable Functional Improvement With Moderate Survivorship Compared With Younger Cohorts: A Systematic Review. Arthroscopy. Published online 14 September 2026. PubMed PMID 42734296.

    More Orthopaedic Updates · Polish version

    This material is for general information and does not replace individual assessment for treatment.

    Content prepared by: Tomasz Poboży - orthopaedic surgeon.

  • CAR-T Cells Made Directly in the Body? Early Results in Autoimmune Neurologic Disease

    General Medical Discoveries · Early human study

    Researchers have reported early results from a method designed to generate CD19 CAR-T cells directly inside the patient using a lentiviral vector, rather than first collecting and modifying cells in a laboratory. Among 16 people with treatment-refractory neurologic autoimmune disorders, the study reported complete B-cell depletion, manageable side effects and preliminary clinical improvement across disease groups. The approach is interesting because it could eventually simplify CAR-T treatment, which is best known from oncology. An orthopaedic surgeon following developments in cell therapy should note that, for now, this is a small early report rather than evidence from a large controlled trial, so larger controlled studies are needed before it can be considered established treatment.

    Source: Cheng Y-H, et al. Lentiviral In Vivo CD19 CAR T-Cell Therapy in Neurologic Autoimmune Disorders. New England Journal of Medicine. Published online 2 September 2026;395:926–929. DOI: 10.1056/NEJMc2603114 · PubMed. Access used for this summary: article page and abstract; bibliographic metadata checked in PubMed on 15 September 2026.

    More General Medical Discoveries · Polish version

    Content prepared by: Tomasz Poboży - orthopaedic surgeon.

  • Lab-Grown Heart Cells: A Step Toward Repairing the Heart After a Heart Attack

    General Medical Discoveries · Animal study

    Researchers produced aggregates of heart muscle cells from human induced pluripotent stem cells and transplanted them into the hearts of monkeys after myocardial infarction. Three months later, substantial, organised human graft tissue was present in the animals’ hearts, and recovery of heart function appeared to vary with the properties of the cardiomyocytes used. Graft-related arrhythmias occurred, although they became less frequent over time. An orthopaedic surgeon following regenerative medicine should distinguish preclinical progress from clinical evidence: this is an important preclinical step toward repairing damaged heart muscle, but it does not yet show that this specific approach is safe or effective in people.

    Source: Gruh I, Martens A, et al. Human iPSC-cardiomyocyte-aggregate cell therapy in non-human primates and correlation of heart recovery with contractile and electrophysiological cardiomyocyte properties. Nature Communications. Published 26 August 2026;17:9066. Source publication · PubMed. Prepared from the public abstract and bibliographic record; full text was not used. Source details checked 15 September 2026.

    More General Medical Discoveries · Polish version

    Content prepared by: Tomasz Poboży - orthopaedic surgeon.